{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:00:24Z","timestamp":1790312424718,"version":"4.1.0"},"reference-count":61,"publisher":"Bioscientifica","issue":"2","content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Differentiating drugs may be able to re-sensitize thyroid carcinomas to radioiodine therapy. Substituted thiazolidinediones (TZDs) belong to the group of oral anti-diabetic drugs that also possess anti-proliferative and pro-apoptotic effects and, potentially, differentiating effects on several cancer cell lines. Some of the effects are mediated via the peroxisome proliferator-activated receptor gamma (PPAR-\u03b3). We investigated the effect of troglitazone, rosiglitazone and pioglitazone on differentiation in normal porcine thyrocytes and in the follicular carcinoma cell lines FTC 133 and FTC 238. Differentiation was investigated by measuring 125I uptake and the expression of sodium-iodide symporter and thyroglobulin proteins. The TZDs were tested in the presence of retinol and retinoic acid. Additionally, proliferation was evaluated by [3H]thymidine uptake and cell number and apoptosis by annexin V-labeling. Controls included tocopherol and unsubstituted thiazolidinedione and co-incubation of the TZDs with the PPAR-\u03b3 antagonist GW9662. PPAR-\u03b3 and retinol X receptor (RXR)-\u03b1 were investigated by immunocytochemistry, Western blot and RT-PCR. Cells derived from the metastasis showed greater responses than cells derived from the primary tumor. Troglitazone showed greater effects than the other TZDs. Troglitazone significantly increased 125I uptake and apoptosis and decreased [3H]thymidine uptake and cell number. The amount of the sodium iodide-symporter in the membrane fraction was significantly increased, while that of thyroglobulin was not influenced by the treatment. Inclusion of antagonist did not abolish these effects. No synergistic effect with any retinoid was detected. All transformed cells expressed PPAR-\u03b3 and RXR-\u03b1 but TZDs did not change their expression.<\/jats:p>\n                  <jats:p>Troglitazone appears to be suited for the re-differentiation treatment of dedifferentiated thyroid carcinoma because its action is twofold. On the one hand it increases differentiation and on the other hand it inhibits proliferation.<\/jats:p>","DOI":"10.1677\/erc.1.00973","type":"journal-article","created":{"date-parts":[[2005,6,9]],"date-time":"2005-06-09T13:38:50Z","timestamp":1118324330000},"page":"291-303","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-8","source":"Crossref","is-referenced-by-count":62,"title":["Action of thiazolidinediones on differentiation, proliferation and apoptosis of normal and transformed thyrocytes in culture"],"prefix":"10.1530","volume":"12","author":[{"given":"Eleonore","family":"Fro\u0308hlich","sequence":"first","affiliation":[{"name":"Medical Clinic (Department of Endocrinology, Metabolism, Nephrology and Pathobiochemistry), Otfried-Muellerstrasse 10, 72076 Tuebingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fausto","family":"Machicao","sequence":"additional","affiliation":[{"name":"Medical Clinic (Department of Endocrinology, Metabolism, Nephrology and Pathobiochemistry), Otfried-Muellerstrasse 10, 72076 Tuebingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Whal","sequence":"additional","affiliation":[{"name":"Medical Clinic (Department of Endocrinology, Metabolism, Nephrology and Pathobiochemistry), Otfried-Muellerstrasse 10, 72076 Tuebingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"2026070905544772300_BAE-ETAL-2003","doi-asserted-by":"crossref","unstructured":"Bae\n            M\n          , Rhee H & Song B 2003 Troglitazone but not rosiglitazone induces G1 cell cycle arrest and apoptosis in human and rat hepatoma cell lines. Toxicology Letters13967\u201375.","DOI":"10.1016\/S037842740200468X"},{"key":"2026070905544772300_BERGE-ETAL-2001","doi-asserted-by":"crossref","unstructured":"Berge\n            K\n          , Tronstad K, Flindt E, Rasmussen T, Madsen L, Kristiansen K & Berge R 2001 Tetradecylthioacetic acid inhibits growth of rat glioma cells ex vivo and in vivo via PPAR-dependent and PPAR-independent pathways. Carcinogenesis221747\u20131755.","DOI":"10.1093\/carcin\/22.11.1747"},{"key":"2026070905544772300_BURSTEIN-ETAL-2003","doi-asserted-by":"crossref","unstructured":"Burstein\n            H\n          , Demetri G, Mueller E, Sarraf P, Spiegelman B & Winer E 2003 Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study. Breast Cancer Research and Treatment79391\u2013397.","DOI":"10.1023\/A:1024038127156"},{"key":"2026070905544772300_CAMPBELL-ETAL-2003","doi-asserted-by":"crossref","unstructured":"Campbell\n            S\n          , Stone W, Whaley S, Qui M & Krishnan K 2003 Gamma tocopherol upregulates peroxisome proliferator activated receptor (PPAR) gamma expression in SW 480 human colon cancer cell lines. BMC Cancer325.","DOI":"10.1186\/1471-2407-3-25"},{"key":"2026070905544772300_CLAY-ETAL-2002","doi-asserted-by":"crossref","unstructured":"Clay\n            C\n          , Monjazeb A, Thorburn J, Chilton F & High K 2002 15-Deoxy-delta12,14-prostaglandin J2-induced apoptosis does not require PPAR gamma in breast cancer cells. Journal of Lipid Research431818\u20131828.","DOI":"10.1194\/jlr.M200224-JLR200"},{"key":"2026070905544772300_DEBROCK-ETAL-2003","doi-asserted-by":"crossref","unstructured":"Debrock\n            G\n          , Vanhentenrijk V, Sciot R, Debiec-Rychter M, Oyen R & Van Oosterom A 2003 A phase II trial with rosiglitazone in liposarcoma patients. British Journal of Cancer891409\u20131412.","DOI":"10.1038\/sj.bjc.6601306"},{"key":"2026070905544772300_DEMETRI-ETAL-1999","doi-asserted-by":"crossref","unstructured":"Demetri\n            G\n          , Fletcher C, Mueller E, Sarraf P, Naujoks R, Campbell N, Spiegelman B & Singer S 1999 Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. PNAS963951\u20133956.","DOI":"10.1073\/pnas.96.7.3951"},{"key":"2026070905544772300_DESMOND-ETAL-2003","unstructured":"Desmond\n            J\n          , Mountford J, Drayson M, Walker E, Hewison M, Ride J, Luong Q, Hayden R, Vanin E & Bunce C 2003 The aldo-keto reductase AKR1C3 is a novel suppressor of cell differentiation that provides a plausible target for the non-cyclooxygenase-dependent antineoplastic actions of nonsteroidal anti-inflammatory drugs. Cancer Research63505\u2013512."},{"key":"2026070905544772300_ELNEMR-ETAL-2000","doi-asserted-by":"crossref","unstructured":"Elnemr\n            A\n          , Ohta T, Iwata K, Ninomia I, Fushida S, Nishimura G, Kitagawa H, Kayahara M, Yamamoto M, Terada T & Miwa K 2000 PPAR gamma ligand (thiazolidinedione) induces growth arrest and differentiation markers of human pancreatic cancer cells. International Journal of Oncology171157\u20131164.","DOI":"10.3892\/ijo.17.6.1157"},{"key":"2026070905544772300_ELSTNER-ETAL-1998","doi-asserted-by":"crossref","unstructured":"Elstner\n            E\n          , Muller C, Koshizuka K, Williamson E, Park D, Asou H, Shintaku P, Said J, Heber D & Koeffler H 1998 Ligands for peroxisome proliferator-activated receptor gamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. PNAS958806\u20138811.","DOI":"10.1073\/pnas.95.15.8806"},{"key":"2026070905544772300_FORTUNATI-ETAL-2004","doi-asserted-by":"crossref","unstructured":"Fortunati\n            N\n          , Catalano M, Arena K, Brignardello E, Piovesan A & Boccuzzi G 2004 Valproic acid induces the expression of the Na+\/I \u2212 symporter and iodine uptake in poorly differentiated thyroid cancer cells. Journal of Clinical Endocrinology and Metabolism891006\u20131009.","DOI":"10.1210\/jc.2003-031407"},{"key":"2026070905544772300_FROHLICH-ETAL-2001","doi-asserted-by":"crossref","unstructured":"Fro\u0308hlich\n            E\n          , Brossart P & Wahl R 2001 Effects of retinoids on porcine thyrocytes under different culture conditions. Histochemical Journal33295\u2013304.","DOI":"10.1023\/A:1017981108387"},{"key":"2026070905544772300_FUJIWARA-AND-HORIKOSHI-2000","unstructured":"Fujiwara\n            T\n           & Horikoshi H 2000 Troglitazone and related compounds: therapeutic potential beyond diabetes. Life Sciences672405\u20132416."},{"key":"2026070905544772300_GORETZKI-ETAL-1990","doi-asserted-by":"crossref","unstructured":"Goretzki\n            P\n          , Frilling A, Simon D & Roeher H 1990 Growth regulation of normal thyroids and thyroid tumors in man. Recent Results in Cancer Research11848\u201363.","DOI":"10.1007\/978-3-642-83816-3_6"},{"key":"2026070905544772300_GRUNWALD-ETAL-1998","unstructured":"Grunwald\n            F\n          , Menzel C, Bender H, Palmedo H, Otte R, Fimmers R, Risse J & Biersack HJ 1998 Redifferentiation therapy-induced radioiodine uptake in thyroid cancer. Journal of Nuclear Medicine391903\u20131906."},{"key":"2026070905544772300_GUPTA-ETAL-2001","doi-asserted-by":"crossref","unstructured":"Gupta\n            R\n          , Brockman J, Sarraf P, Willson T & DuBois R 2001 Target genes of peroxisome proliferator-activated receptor gamma in colorectal cancer cells. Journal of Biological Chemistry27629681\u201329687.","DOI":"10.1074\/jbc.M103779200"},{"key":"2026070905544772300_HEYMAN-ETAL-1992","doi-asserted-by":"crossref","unstructured":"Heyman\n            R\n          , Mangelsdorf D, Dyck J, Stein R, Eichele G, Evans R & Thaller C 1992 9-cis retinoic acid is a high affinity ligand for the retinoid X receptor. Cell68397\u2013406.","DOI":"10.1016\/0092-8674(92)90479-V"},{"key":"2026070905544772300_HUANG-ETAL-2005","doi-asserted-by":"crossref","unstructured":"Huang\n            J\n          , Shiau C, Yang Y, Kulp S, Chen K, Brueggemeier R, Shapiro C & Chen C 2005 Peroxisome proliferator-activated receptor \u03b3-independent ablation of cyclin d1 by thiazolidenediones and their derivatives in breast cancer cells. Molecular Pharmacology671342\u20131348.","DOI":"10.1124\/mol.104.007732"},{"key":"2026070905544772300_KAWA-ETAL-2002","doi-asserted-by":"crossref","unstructured":"Kawa\n            S\n          , Nikaido T, Unno H, Usuda N, Nakayama K & Kiyosawa K 2002 Growth inhibition and differentiation of pancreatic cancer cell lines by PPAR gamma ligand troglitazone. Pancreas241\u20137.","DOI":"10.1097\/00006676-200201000-00001"},{"key":"2026070905544772300_KAWAKAMI-ETAL-2002","doi-asserted-by":"crossref","unstructured":"Kawakami\n            S\n          , Arai G, Hayashi T, Fujii Y, Xia G, Kageyama Y & Kihara K 2002 PPAR gamma ligands suppress proliferation of human urothelial basal cells in vitro.Journal of Cellular Physiology191310\u2013319.","DOI":"10.1002\/jcp.10099"},{"key":"2026070905544772300_KITAMURA-ETAL-1999","doi-asserted-by":"crossref","unstructured":"Kitamura\n            S\n          , Miyazaki Y, Shinomura Y, Kondo S, Kanayama S & Matsuzawa Y 1999 Peroxisome proliferator-activated receptor gamma induces growth arrest and differentiation markers of human colon cancer cells. Japanese Journal of Cancer Research9075\u201380.","DOI":"10.1111\/j.1349-7006.1999.tb00668.x"},{"key":"2026070905544772300_KITAZONO-ETAL-2001","doi-asserted-by":"crossref","unstructured":"Kitazono\n            M\n          , Robey R, Zhan Z, Sarlis N, Skarulis M, Aikou T, Bates S & Fojo T 2001 Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)\/I(\u2212) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. Journal of Clinical Endocrinology and Metabolism863430\u20133435.","DOI":"10.1210\/jcem.86.7.7621"},{"key":"2026070905544772300_KLOPPER-ETAL-2004","doi-asserted-by":"crossref","unstructured":"Klopper\n            J\n          , Hays W, Sharma V, Baumbusch M, Hershman J & Haugen B 2004 Retinoid X receptor-gamma and peroxisome proliferator-activated receptor-gamma expression predicts thyroid carcinoma cell response to retinoid and thiazolidinedione treatment. Molecular Cancer Therapy31011\u20131020.","DOI":"10.1158\/1535-7163.1011.3.8"},{"key":"2026070905544772300_KNOUFF-AND-AUWERX-2004","doi-asserted-by":"crossref","unstructured":"Knouff\n            C\n           & Auwerx J 2004 Peroxisome proliferator-activated receptor-\u03b3 cells for activation in moderation: lessons from genetics and pharmacology. Endocrine Reviews25899\u2013918.","DOI":"10.1210\/er.2003-0036"},{"key":"2026070905544772300_KUBOTA-ETAL-1998","unstructured":"Kubota\n            T\n          , Koshizuka K, Williamson E, Asou H, Said J, Holden S, Miyoshi I & Koeffler H 1998 Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo.Cancer Research583344\u20133352."},{"key":"2026070905544772300_KULKE-ETAL-2002","doi-asserted-by":"crossref","unstructured":"Kulke\n            M\n          , Demetri G, Sharpless N, Ryan D, Shivdasani R, Clark J, Spiegelman B, Kim H, Mayer R & Fuchs C 2002 A phase II study of troglitazone, an activator of the PPAR gamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer. Cancer Journal8395\u2013399.","DOI":"10.1097\/00130404-200209000-00010"},{"key":"2026070905544772300_KUREBAYASHI-ETAL-2000","doi-asserted-by":"crossref","unstructured":"Kurebayashi\n            J\n          , Tanaka K, Otsuki T, Moriya T, Kunisue H, Uno M & Sonoo H 2000 All-trans-retinoic acid modulates expression levels of thyroglobulin and cytokines in a new human poorly differentiated papillary thyroid carcinoma cell line, KTC-1. Journal of Clinical Endocrinology and Metabolism852889\u20132896.","DOI":"10.1210\/jc.85.8.2889"},{"key":"2026070905544772300_LAEMMLI-1970","doi-asserted-by":"crossref","unstructured":"Laemmli\n            UK\n          \n          1970 Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature227680\u2013685.","DOI":"10.1038\/227680a0"},{"key":"2026070905544772300_LEBOVITZ-2002","doi-asserted-by":"crossref","unstructured":"Lebovitz\n            H\n          \n          2002 Differentiating members of the thiazolidinedione class: a focus on safety. Diabetes Metabolism Research and Reviews18 Suppl 2 S23\u2013S29.","DOI":"10.1002\/dmrr.252"},{"key":"2026070905544772300_LEGRO-ETAL-2003","doi-asserted-by":"crossref","unstructured":"Legro\n            R\n          , Azziz R, Ehrmann D, Fereshetian A, O\u2019Keefe M & Ghazzi M 2003 Minimal response of circulating lipids in women with polycystic ovary syndrome to improvement in insulin sensitivity with troglitazone. Journal of Clinical Endocrinology and Metabolism885137\u20135144.","DOI":"10.1210\/jc.2003-030044"},{"key":"2026070905544772300_LENHARD-2001","unstructured":"Lenhard\n            J\n          \n          2001 PPAR gamma\/RXR as a molecular target for diabetes. Receptors Channels7249\u2013258."},{"key":"2026070905544772300_MARSHALL-ETAL-2002","doi-asserted-by":"crossref","unstructured":"Marshall\n            J\n          , Rizvi N, Kauh J, Dahut W, Figuera M, Kang M, Figg W, Wainer I, Chaissang C, Li M & Hawkins M 2002 A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. Journal of Experimental Therapeutics and Oncology2325\u2013332.","DOI":"10.1046\/j.1359-4117.2002.01039.x"},{"key":"2026070905544772300_MARX-ETAL-2001","doi-asserted-by":"crossref","unstructured":"Marx\n            N\n          , Libby P & Plutzky J 2001 Peroxisome proliferator-activated receptors (PPARs) and their role in the vessel wall: possible mediators of cardiovascular risk? Journal of Cardiovascular Risk8203\u2013210.","DOI":"10.1177\/174182670100800404"},{"key":"2026070905544772300_MUELLER-ETAL-2000","doi-asserted-by":"crossref","unstructured":"Mueller\n            E\n          , Smith M, Sarraf P, Kroll T, Aiyer A, Kaufman D, Oh W, Demetri G, Figg W, Zhou X, Eng C, Spiegelman B & Kantoff P 2000 Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. PNAS9710990\u201310995.","DOI":"10.1073\/pnas.180329197"},{"key":"2026070905544772300_NAMBA-ETAL-1993","doi-asserted-by":"crossref","unstructured":"Namba\n            H\n          , Yamashita S, Morita S, Villadolid MC, Kimura H, Yokoyama N, Izumi M, Ishikawa N, Ito K & Nagataki S 1993 Retinoic acid inhibits human thyroid peroxidase and thyroglobulin gene expression in cultured human thyrocytes. Journal of Endocrinological Investigation1687\u201393.","DOI":"10.1007\/BF03347654"},{"key":"2026070905544772300_NILES-ETAL-1990","doi-asserted-by":"crossref","unstructured":"Niles\n            RM\n          , Loewy BP & Brown K 1990 The effect of retinoic acid on growth and protooncogene expression in hamster tracheal epithelial cells. American Journal of Respiratory Cell and Molecular Biology2365\u2013371.","DOI":"10.1165\/ajrcmb\/2.4.365"},{"key":"2026070905544772300_OHTA-ETAL-2001","doi-asserted-by":"crossref","unstructured":"Ohta\n            K\n          , Endo T, Haraguchi K, Hershman J & Onaya T 2001 Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. Journal of Clinical Endocrinology and Metabolism862170\u20132177.","DOI":"10.1210\/jcem.86.5.7493"},{"key":"2026070905544772300_OKUNO-ETAL-1998","doi-asserted-by":"crossref","unstructured":"Okuno\n            A\n          , Tamemoto H, Tobe K, Ueki K, Mori Y, Iwamoto K, Umesono K, Akanuma Y, Fujiwara T, Horikoshi H, Yazaki Y & Kadowaki T 1998 Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. Journal of Clinical Investigation1011354\u20131361.","DOI":"10.1172\/JCI1235"},{"key":"2026070905544772300_OTTO-ETAL-2002","doi-asserted-by":"crossref","unstructured":"Otto\n            C\n          , Lehrke M & Goke B 2002 Novel insulin sensitizers: pharmacogenomic aspects. Pharmacogenomics399\u2013116.","DOI":"10.1517\/14622416.3.1.99"},{"key":"2026070905544772300_PALAKURTHI-ETAL-2001","unstructured":"Palakurthi\n            S\n          , Aktas H, Grubissich L, Mortensen R & Halperin J 2001 Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor gamma and mediated by inhibition of translation initiation. Cancer Research616213\u20136218."},{"key":"2026070905544772300_QIAO-ETAL-1996","doi-asserted-by":"crossref","unstructured":"Qiao\n            L\n          , Koutsos M, Tsai L, Kozoni V, Guzman J, Shiff S & Rigas B 1996 Staurosporine inhibits the proliferation, alters the cell cycle distribution and induces apoptosis in HT-29 human colon adenocarcinoma cells. Cancer Letters10783\u201389.","DOI":"10.1016\/0304-3835(96)04346-7"},{"key":"2026070905544772300_SARRAF-ETAL-1998","doi-asserted-by":"crossref","unstructured":"Sarraf\n            P\n          , Mueller E, Jones D, King F, DeAngelo D, Partridge J, Holden S, Chen L, Singer S, Fletcher C & Spiegelman B 1998 Differentiation and reversal of malignant changes in colon cancer through PPAR gamma. Nature Medicine41046\u20131052.","DOI":"10.1038\/2030"},{"key":"2026070905544772300_SATO-ETAL-2000","doi-asserted-by":"crossref","unstructured":"Sato\n            H\n          , Ishihara S, Kawashima K, Moriyama N, Suetsugu H, Kazumori H, Okuyama T, Rumi M, Fukuda R, Nagasue N & Kinoshita Y 2000 Expression of peroxisome proliferator-activated receptor (PPAR) gamma in gastric cancer and inhibitory effects of PPAR gamma agonists. British Journal of Cancer831394\u20131400.","DOI":"10.1054\/bjoc.2000.1457"},{"key":"2026070905544772300_SATOH-ETAL-2002","doi-asserted-by":"crossref","unstructured":"Satoh\n            T\n          , Toyoda M, Hoshino H, Monden T, Yamada M, Shimizu H, Miyamoto K, Mori M, Yamada M & Mori M 2002 Activation of peroxisome proliferator-activated receptor-gamma stimulates the growth arrest and DNA-damage inducible 153 gene in non-small cell lung carcinoma cells Oncogene212171\u20132180.","DOI":"10.1038\/sj.onc.1205279"},{"key":"2026070905544772300_SCHMUTZLER-AND-KOHRLE-2000","doi-asserted-by":"crossref","unstructured":"Schmutzler\n            C\n           & Ko\u0308hrle J 2000 Retinoic acid redifferentiation therapy for thyroid cancer. Thyroid10393\u2013406.","DOI":"10.1089\/thy.2000.10.393"},{"key":"2026070905544772300_SCHMUTZLER-ETAL-1997","doi-asserted-by":"crossref","unstructured":"Schmutzler\n            C\n          , Winzer R, Meissner-Weigl J & Ko\u0308hrle J 1997 Retinoic acid increases sodium\/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in nontransformed FRTL-5 rat thyroid cells. Biochemical and Biophysical Research Communications240832\u2013838.","DOI":"10.1006\/bbrc.1997.7715"},{"key":"2026070905544772300_DEL-SENNO-ETAL-1993","doi-asserted-by":"crossref","unstructured":"del Senno\n            L\n          , Rossi R, Gandini D, Piva R & Franceschetti P 1993 Retinoic acid-induced decrease of DNA synthesis and peroxidase mRNA levels in human thyroid cells expressing retinoic acid receptor alpha mRNA. Life Sciences531039\u20131048.","DOI":"10.1016\/0024-3205(93)90256-3"},{"key":"2026070905544772300_SIMON-ETAL-1996","doi-asserted-by":"crossref","unstructured":"Simon\n            D\n          , Ko\u0308hrle J, Schmutzler C, Mainz K, Reiners C & Roher H 1996 Redifferentiation therapy of differentiated thyroid carcinoma with retinoic acid: basics and first clinical results. Experimental and Clinical Endocrinology and Diabetes104 Suppl 4 13\u201315.","DOI":"10.1055\/s-0029-1211692"},{"key":"2026070905544772300_SIMON-ETAL-1998","doi-asserted-by":"crossref","unstructured":"Simon\n            D\n          , Ko\u0308hrle J, Reiners C, Boerner AR, Schmutzler C, Mainz K, Goretzki PE & Roeher HD 1998 Redifferentiation therapy with retinoids: therapeutic option for advanced follicular and papillary thyroid carcinoma. World Journal of Surgery22569\u2013574.","DOI":"10.1007\/s002689900436"},{"key":"2026070905544772300_SIMON-ETAL-2002","doi-asserted-by":"crossref","unstructured":"Simon\n            D\n          , Korber C, Krausch M, Segering J, Groth P, Gorges R, Grunwald F, Muller-Gartner H, Schmutzler C, Ko\u0308hrle J, Roher H & Reiners C 2002 Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study. European Journal of Nuclear Medicine and Molecular Imaging29775\u2013782.","DOI":"10.1007\/s00259-001-0737-6"},{"key":"2026070905544772300_TAKEDA-ETAL-2001","doi-asserted-by":"crossref","unstructured":"Takeda\n            K\n          , Ichiki T, Tokunou T, Iino N & Takeshita A 2001 15-Deoxy-delta 12,14-prostaglandin J2 and thiazolidinediones activate the MEK\/ERK pathway through phosphatidylinositol 3-kinase in vascular smooth muscle cells. Journal of Biological Chemistry27648950\u201348955.","DOI":"10.1074\/jbc.M108722200"},{"key":"2026070905544772300_TEBOUL-ETAL-1995","doi-asserted-by":"crossref","unstructured":"Teboul\n            L\n          , Gaillard D, Staccini L, Inadera H, Amri E & Grimaldi P 1995 Thiazolidinediones and fatty acids convert myogenic cells into adipose-like cells. Journal of Biological Chemistry27028183\u201328187.","DOI":"10.1074\/jbc.270.47.28183"},{"key":"2026070905544772300_TOWBIN-ETAL-1979","doi-asserted-by":"crossref","unstructured":"Towbin\n            H\n          , Staehelin T & Gordon J 1979 Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. PNAS764350\u20134354.","DOI":"10.1073\/pnas.76.9.4350"},{"key":"2026070905544772300_TROUTTET-MASSON-ETAL-2004","doi-asserted-by":"crossref","unstructured":"Trouttet-Masson\n            S\n          , Selmi-Ruby S, Bernier-Valentin F, Porra V, Berger-Dutrieux N, Decaussin M, Peix J, Perrin A, Bournaud C, Orgiazzi J, Borson-Chazot F, Franc B & Rousset B 2004 Evidence for transcriptional and posttranscriptional alterations of the sodium\/iodide symporter expression in hypofunctioning benign and malignant thyroid tumors. American Journal of Pathology16525\u201334.","DOI":"10.1016\/S0002-9440(10)63272-5"},{"key":"2026070905544772300_TSUBOUCHI-ETAL-2000","doi-asserted-by":"crossref","unstructured":"Tsubouchi\n            Y\n          , Sano H, Kawahito Y, Mukai S, Yamada R, Kohno M, Inoue K, Hla T & Kondo M 2000 Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis. Biochemical and Biophysical Research Communications270400\u2013405.","DOI":"10.1006\/bbrc.2000.2436"},{"key":"2026070905544772300_WAHL-ETAL-1992","doi-asserted-by":"crossref","unstructured":"Wahl\n            R\n          , Brossart P, Eizenberger D, Schuch H & Kallee E 1992 Direct effects of protirelin (TRH) on cultured porcine thyrocytes. Journal of Endocrinological Investigation15345\u2013351.","DOI":"10.1007\/BF03348750"},{"key":"2026070905544772300_YEE-ETAL-1999","doi-asserted-by":"crossref","unstructured":"Yee\n            L\n          , Sabourin C, Liu L, Li H, Smith P, Seewaldt V & Kniss D 1999 Peroxisome proliferator-activated receptor gamma activation in human breast cancer. International Journal of Oncology15967\u2013973.","DOI":"10.3892\/ijo.15.5.967"},{"key":"2026070905544772300_YOSHIMURA-ETAL-2003","doi-asserted-by":"crossref","unstructured":"Yoshimura\n            R\n          , Matsuyama M, Segawa Y, Hase T, Mitsuhashi M, Tsuchida K, Wada S, Kawahito Y, Sano H & Nakatani T 2003 Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. International Journal of Cancer104597\u2013602.","DOI":"10.1002\/ijc.10980"},{"key":"2026070905544772300_YOSHIZAWA-ETAL-2002","doi-asserted-by":"crossref","unstructured":"Yoshizawa\n            K\n          , Cioca D, Kawa S, Tanaka E & Kiyosawa K 2002 Peroxisome proliferator-activated receptor gamma ligand troglitazone induces cell cycle arrest and apoptosis of hepatocellular carcinoma cell lines. Cancer952243\u20132251.","DOI":"10.1002\/cncr.10906"},{"key":"2026070905544772300_YOUNG-ETAL-1998","doi-asserted-by":"crossref","unstructured":"Young\n            P\n          , Buckle D, Cantello B, Chapman H, Clapham J, Coyle P, Haigh D, Hindley R, Holder J, Kallender H, Latter A, Lawrie K, Mossakowska D, Murphy G, Roxbee Cox L & Smith S 1998 Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma. Journal of Pharmacology and Experimental Therapy284751\u2013759.","DOI":"10.1016\/S0022-3565(24)37268-4"},{"key":"2026070905544772300_ZANDER-ETAL-2002","doi-asserted-by":"crossref","unstructured":"Zander\n            T\n          , Kraus J, Grommes C, Schlegel U, Feinstein D, Klockgether T, Landreth G, Koenigsknecht J & Heneka M 2002 Induction of apoptosis in human and rat glioma by agonists of the nuclear receptor PPAR gamma. Journal of Neurochemistry811052\u20131060.","DOI":"10.1046\/j.1471-4159.2002.00899.x"}],"updated-by":[{"DOI":"10.1677\/erc.1.00973e","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2005,9,1]],"date-time":"2005-09-01T00:00:00Z","timestamp":1125532800000}}],"container-title":["Endocrine-Related Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/12\/2\/291\/149562\/0120291.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/12\/2\/291\/149562\/0120291.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T09:55:06Z","timestamp":1783590906000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article\/12\/2\/291\/26634\/Action-of-thiazolidinediones-on-differentiation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6,1]]},"references-count":61,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,6,1]]}},"URL":"https:\/\/doi.org\/10.1677\/erc.1.00973","relation":{},"ISSN":["1479-6821","1351-0088"],"issn-type":[{"value":"1479-6821","type":"electronic"},{"value":"1351-0088","type":"print"}],"subject":[],"published":{"date-parts":[[2005,6,1]]}}}